Document is current
Any future updates will be listed below
-
Authors
Li, Zhipeng https://orcid.org/0000-0001-8806-9667
Ferguson, Lucas
Deol, Kirandeep K.
Roberts, Melissa A.
Magtanong, Leslie https://orcid.org/0000-0002-0894-3156
Hendricks, Joseph M.
Mousa, Gergey Alzaem
Kilinc, Seda
Schaefer, Kaitlin
Wells, James A. https://orcid.org/0000-0001-8267-5519
Bassik, Michael C. https://orcid.org/0000-0001-5185-8427
Goga, Andrei https://orcid.org/0000-0001-9127-0986
Dixon, Scott J. https://orcid.org/0000-0001-6230-8199
Ingolia, Nicholas T. https://orcid.org/0000-0002-3395-1545
Olzmann, James A. https://orcid.org/0000-0001-7751-8316
-
Funding
Funding for this research was provided by:
American Cancer Society (RSG-19-192-01)
Melanoma Research Alliance (620458)
U.S. Department of Health & Human Services | National Institutes of Health (R01GM112948, T32GM007232, F31DK121477, 2T32CA108462, R01CA223817, 1R01GM122923)
Chan Zuckerberg Biohub, Miller Institute
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-18-1-0713)
Mark Foundation
- License Information
-
More Information
Article History
Received: 18 February 2022
Accepted: 6 April 2022
First Online: 30 May 2022
Competing interests
: S.J.D. is a cofounder of Prothegen Inc. and a member of the advisory board for Ferro Therapeutics and Hillstream Biopharma. J.A.O. is a member of the advisory board for Vicinitas Therapeutics. S.J.D. and J.A.O. have patent applications related to ferroptosis.
